Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 4;12:720345. doi: 10.3389/fphar.2021.720345

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Montesel, Bucolo, Sallo and Eandi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Representative case of a naïve patient presenting with choroidal neovascularization secondary to neovascular age-related macular degeneration treated with monthly intravitreal brolucizumab (IVT-B). (A) Baseline fluorescein angiography demonstrates the presence of a subfoveal type 2 choroidal neovascularization with adjacent subretinal hemorrhage. (B) Optical coherence tomography (OCT) B-scan at baseline reveals the presence of mild subretinal fluid (SRF) and subretinal hyperreflective material (SHRM) in the foveal area. An epiretinal membrane is also visible. (C) OCT B-scan 1 month after the first IVT-B shows the resolution of the SRF and the SHRM with reduction of the central subfield thickness from 375 to 295 µm. (D) OCT B-scans at 2-month and (E) at 3-month visit demonstrate the absence of recurrences and a dry macula after the loading dose. Best-corrected visual acuity improved from 20/100 to 20/50.